ALLMedicine™ Cardiovascular Risk Management Center

Feb 21st, 2021 - Obesity and cardiovascular risk management is a critical way to reduce healthcare resource pressure.|2021|Chen L,Hao G,|

Feb 2nd, 2021 - Cardiovascular disease (CVD) is the main cause of mortality among non-alcoholic fatty liver disease (NAFLD) patients. The aim was to explore the level of knowledge and clinical management of cardiovascular risk (CVR) in NAFLD patients by Digestive...

Sep 18th, 2020 - Cognitive impairment and dementia following cerebrovascular disease are increasingly common in the UK. One potential strategy to prevent post-stroke cognitive decline is multimodal vascular risk factor management. However, its efficacy remains unc...

Sep 18th, 2020 - Cardiovascular diseases (CVDs) and diabetes mellitus (DM) are among the leading cause of morbidity and mortality in low-and-middle-income countries (LMICs) but evidence in these contexts regarding the effectiveness of primary prevention interventi...

Jul 13th, 2020 - To evaluate the impact of changes in elective Abdominal Aortic Aneurysm (AAA) management on life-expectancy of AAA patients. Over the past decades AAA repair underwent substantial changes, that is, the introduction of EVAR and implementation of in...

Nov 25th, 2018 - Despite major therapeutic advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D) (1). Over that time, the prevalence of.

Nov 9th, 2018 - The recommendations listed in the present guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLIN.

Dec 31st, 2017 - Atherosclerotic cardiovascular disease (ASCVD)—defined as coronary heart disease, cerebrovascular disease, or peripheral arterial disease presumed to be of atherosclerotic origin—is the leading cause of morbidity and mortality for individuals with.

Sep 4th, 2017 - In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)–cholesterol lowering in the management of atherosclerotic cardiovascular.

Sep 23rd, 2009 - To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). A multidisciplinary expert committee was convened as a t...

Feb 28th, 2021 - Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These ben...

Feb 28th, 2021 - Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarct...

Feb 28th, 2021 - Atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been...

Feb 22nd, 2021 - Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarct...

Feb 21st, 2021 - Obesity and cardiovascular risk management is a critical way to reduce healthcare resource pressure.|2021|Chen L,Hao G,|

Oct 4th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's  Coronavirus Resource Center. As the COVID-19 pandemic drove down the number of primary care visits and altered the method — moving many to telehealth appointments instead of ...

May 21st, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape' Coronavirus Resource Center. A new article outlines the many ways in which the COVID-19 pandemic necessitates new considerations beyond traditional cardiovascular risk manageme...

May 21st, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape' Coronavirus Resource Center. A new article outlines the many ways in which the COVID-19 pandemic necessitates new considerations beyond traditional cardiovascular risk manageme...

Aug 17th, 2018 - Two studies published in the New England Journal of Medicine support managing cardiovascular risk in patients with type 2 diabetes. Also today, spontaneous intracranial hypotension is a triple misnomer, prolonged antimalarial therapy is linked to.

Aug 15th, 2018 - The second study, which included 271,174 patients with T2DM from the Swedish National Diabetes Register and 1,355,870 controls, examined five risk factors: elevated glycated hemoglobin level, elevated low-density lipoprotein cholesterol level, alb.